Novartis says it knew of Zolgensma data problems before U.S. approval

Business Aug 8, 2019

Novartis says it knew of Zolgensma data problems before U.S. approval

Swiss Drugmaker Novartis AG on Wednesday said it knew about discrepancies in data it submitted to regulators as it sought approval of its more than $2 million gene therapy Zolgensma, but delayed notifying authorities until it completed an internal investigation. Novartis faces possible civil or ...

World / Science & Health Jul 9, 2015

Progress reported in using gene therapy for deafness

Gene therapy for deafness is moving closer to reality, with new research on Wednesday showing the technique for fixing faulty DNA can improve responses in mice with genetic hearing loss. Separately, a clinical trial backed by Novartis is under way to help a different group ...

Business Feb 3, 2015

Novartis Japan unit faces business suspension order

The health ministry will order a business suspension of around 15 days for a Japanese unit of Swiss pharmaceutical maker Novartis AG for not reporting serious side effects of its drugs, sources close to the matter said on Monday. Tokyo-based Novartis Pharma K.K. would be ...